Trial Profile

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Censavudine (Primary)
Indications Progressive supranuclear palsy
Focus Adverse reactions
Sponsors Transposon Therapeutics

Most Recent Events

21 May 2024 According to an Transposon Therapeutics media release, the the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TPN-101 for progressive supranuclear palsy (PSP), supported by data from this study.
13 Feb 2024 According to an Transposon Therapeutics media release, announced final results at the hybrid AD/PD™ 2024: 18th International Conference on Alzheimer's and Parkinson's Diseases. The meeting will take place online and in Lisbon, Portugal, from March 5-9, 2024.
13 Feb 2024 Results published in the Transposon Therapeutics Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com